Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 86

Similar articles for PubMed (Select 21942254)

1.

Oligonucleotides: a multi-targeted approach for the treatment of respiratory diseases.

Ferrari N, Seguin R, Renzi P.

Future Med Chem. 2011 Oct;3(13):1647-62. doi: 10.4155/fmc.11.108. Review.

PMID:
21942254
2.

Respirable antisense oligonucleotides: a new, third drug class targeting respiratory disease.

Nyce J.

Curr Opin Allergy Clin Immunol. 2002 Dec;2(6):533-6. Review.

PMID:
14752337
3.

Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease.

S├ęguin RM, Ferrari N.

Expert Opin Investig Drugs. 2009 Oct;18(10):1505-17. doi: 10.1517/13543780903179294. Review.

PMID:
19715448
4.

Oligonucleotides: New therapeutic approaches for asthma and chronic obstructive pulmonary disease.

Parry-Billings M, Ferrari N, Seguin R.

Curr Opin Investig Drugs. 2010 Nov;11(11):1276-85.

PMID:
21157647
5.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
6.

The future of antisense oligonucleotides in the treatment of respiratory diseases.

Ulanova M, Schreiber AD, Befus AD.

BioDrugs. 2006;20(1):1-11. Review.

PMID:
16573347
7.

Phosphatidylinositol 3-kinase isoforms as targets in respiratory disease.

Marwick JA, Chung KF, Adcock IM.

Ther Adv Respir Dis. 2010 Feb;4(1):19-34. doi: 10.1177/1753465809352792. Epub 2010 Jan 5. Review.

PMID:
20051446
8.

Emerging drugs for asthma.

Walsh GM.

Expert Opin Emerg Drugs. 2008 Dec;13(4):643-53. doi: 10.1517/14728210802591378 . Review. Erratum in: Expert Opin Emerg Drugs. 2009 Mar;14(1):205.

PMID:
19046132
9.

Clinical evaluation of new therapies for treatment of mucus hypersecretion in respiratory diseases.

Disse B.

Novartis Found Symp. 2002;248:254-72; discussion 272-6, 277-82. Review.

PMID:
12568499
10.

[Oligonucleotide therapeutics - an emerging novel class of compounds].

Wacheck V.

Wien Med Wochenschr. 2006 Sep;156(17-18):481-7. Review. German.

PMID:
17041803
11.

Current and future therapies for airway mucus hypersecretion.

Barnes PJ.

Novartis Found Symp. 2002;248:237-49; discussion 249-53, 277-82. Review.

PMID:
12568498
12.

Inhibition of PI-3 kinase for treating respiratory disease: good idea or bad idea?

Thomas M, Owen C.

Curr Opin Pharmacol. 2008 Jun;8(3):267-74. doi: 10.1016/j.coph.2008.02.004. Epub 2008 Apr 3. Review.

PMID:
18394961
13.

[Mucolytics in acute and chronic respiratory tract disorders. II. Uses for treatment and antioxidant properties].

Kupczyk M, Kuna P.

Pol Merkur Lekarski. 2002 Mar;12(69):248-52. Review. Polish.

PMID:
12053601
14.

Novel signal transduction modulators for the treatment of airway diseases.

Barnes PJ.

Pharmacol Ther. 2006 Jan;109(1-2):238-45. Epub 2005 Sep 19. Review.

PMID:
16171872
15.
16.

Cilomilast.

Schachter EN.

Drugs Today (Barc). 2006 Apr;42(4):237-47. Review.

PMID:
16703120
17.

Drug development for cancer chemoprevention: focus on molecular targets.

Johnson KA, Brown PH.

Semin Oncol. 2010 Aug;37(4):345-58. doi: 10.1053/j.seminoncol.2010.05.012. Review.

PMID:
20816505
19.

The use of leukotriene modifying drugs in asthma and other respiratory diseases.

Corless JA, Paracha M.

Curr Drug Targets Inflamm Allergy. 2002 Sep;1(3):271-5. Review.

PMID:
14561192
20.

Diet and obstructive lung diseases.

Romieu I, Trenga C.

Epidemiol Rev. 2001;23(2):268-87. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk